Biomerica Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>BI</div>
BMRA -- USA Stock  

USD 5.70  0.36  5.94%

Let's first try to go over why Biomerica investors are seeking stability amid unprecedented economic uncertainty. Biomerica is currently traded for 6.89. The entity has historical hype elasticity of 0.78. The average price elasticity to hype of competition is about -0.18. The firm is forecasted to increase in value after the next press release, with the price going to jump to 7.67. The current volatility of headline impact on the company stock price is is way over 100 percent making price predictions on social media along less reliable. The price jump on the next news is estimated to be 11.32%, whereas the daily expected return is currently at 0.72%. Given the investment horizon of 30 days, the next forecasted announcement will be in about 5 days.
Published over three months ago
View all stories for Biomerica | View All Stories
Is Biomerica (NASDAQ:BMRA) gaining more confidence from investors?
On a scale of 0 to 100, Biomerica holds a performance score of 6. The firm shows a Beta (market volatility) of 0.2004, which signifies not very significant fluctuations relative to the market. Let's try to break down what Biomerica's beta means in this case. As returns on the market increase, Biomerica returns are expected to increase less than the market. However, during the bear market, the loss on holding Biomerica will be expected to be smaller as well. Although it is vital to follow Biomerica historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. The philosophy towards foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-one technical indicators for Biomerica, which you can use to evaluate the performance of the firm. Please makes use of Biomerica maximum drawdown, and the relationship between the information ratio and downside variance to make a quick decision on whether Biomerica price patterns will revert.
The successful prediction of Biomerica stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Biomerica, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Biomerica based on Biomerica hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Biomerica's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Biomerica's related companies.

Use Technical Analysis to project Biomerica expected Price

Biomerica technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Biomerica technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Biomerica trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Biomerica utilizes its cash?

To perform a cash flow analysis of Biomerica, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Biomerica is receiving and how much cash it distributes out in a given period. The Biomerica cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Biomerica Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (3.87 Million)

Acquisition by Sloan Steven of 25000 shares of Biomerica subject to Rule 16b-3

Legal trades by Biomerica insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Biomerica insider trading alert for grant of non-qualified stock option by Sloan Steven, Chief Financial Officer, on 11th of December 2020. This event was filed by Biomerica Inc with SEC on 2020-12-11. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Biomerica Investor Appetite?

The current price rise of Biomerica could raise concerns from investors as the firm closed today at a share price of 5.86 on very low momentum in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in October. The stock standard deviation of daily returns for 30 days investing horizon is currently 7.54. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Biomerica partners.
 2017 2018 2019 2020 (projected)
Book Value per Share0.510.431.41.16
Asset Turnover1.131.010.680.75

Cost of Revenue Breakdown

Biomerica Cost of Revenue is increasing over the years with slightly volatile fluctuation. Cost of Revenue is expected to dwindle to about 4.8 M. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. Biomerica Cost of Revenue is projected to increase significantly based on the last few years of reporting. The past year's Cost of Revenue was at 4.91 Million
20133.45 Million
20143.42 Million
20153.62 Million
20163.77 Million
20173.81 Million
20183.91 Million
20194.91 Million
20204.82 Million

Can Biomerica build up on the current rise?

Current variance is at 56.32. Biomerica is displaying above-average volatility over the selected time horizon. Investors should scrutinize Biomerica independently to ensure intended market timing strategies are aligned with expectations about Biomerica volatility.

Our Conclusion on Biomerica

Whereas other entities within the diagnostics & research industry are still a little expensive, even after the recent corrections, Biomerica may offer a potential longer-term growth to investors. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither acquire new shares of Biomerica nor exit your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Biomerica.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Biomerica. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to